Company intelligence / Profile preview

Centro Avançado de Medicina Psicodélica

Natal, Rio Grande do Norte, Brazileduc.camp-sci.com ↗

Ownership: Private
Development stage: Phase 1

Overview

CAMP is focused on advancing the therapeutic use of psychedelics, particularly DMT and ketamine, through research and clinical trials. They aim to develop accessible and scalable therapeutic solutions for mental health disorders.

Therapeutic areas: Psychiatry
Modalities: Small molecules (specifically psychedelics like DMT and ketamine)
Industry: Biotech

Drug pipeline

2 assets

dimethyltryptamine

Phase 1

Indications: Treatment-resistant depression

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Centro Avançado de Medicina Psicodélica.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Centro Avançado de Medicina Psicodélica.

Explore the full profile